The Technical Analyst
Corcept Therapeutics Inc [CORT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Corcept Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
7.35% $23.94
America/New_York / 23 apr 2024 @ 11:52
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 478.20 mill |
| EPS: | 0.940 |
| P/E: | 25.47 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 103.52 mill |
| Avg Daily Volume: | 1.182 mill |
| RATING 2024-04-22 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 25.47 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 4.33x |
| Company: PE 25.47 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$65.50 (173.58%) $41.56 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 23.04 - 24.83 ( +/- 3.74%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-10 | Mahoney David L | Buy | 27 806 | Common Stock |
| 2024-04-10 | Mahoney David L | Buy | 30 000 | Common Stock |
| 2024-04-10 | Mahoney David L | Sell | 2 194 | Common Stock |
| 2024-04-10 | Mahoney David L | Sell | 27 806 | Common Stock |
| 2024-04-10 | Mahoney David L | Sell | 30 000 | Stock option (right to buy) |
| INSIDER POWER |
|---|
| 62.30 |
| Last 97 transactions |
| Buy: 1 925 494 | Sell: 448 997 |
Forecast:
13:32 - $23.94
Live Trading Signals (every 1 min)
Forecast
1: 12:02 - $23.93
Forecast 2: 12:52 - $23.91
Forecast 3: 13:32 - $23.94
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $23.94 (7.35% ) |
| Volume | 0.913 mill |
| Avg. Vol. | 1.182 mill |
| % of Avg. Vol | 77.24 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CORT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $22.17 | N/A | Active |
|---|
CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Latest Press Releases
2024-04-18 12:15:00 - Press Release
Levi & Korsinsky, Llp Notifies Shareholders Of Corcept Therapeutics Incorporated (cort) An Upcoming Claims Deadline In A Class Action Settlement
New york, ny / accesswire / april 18, 2024 / levi & korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against corcept therapeutics incorporated (nasdaq:cort). the settlement provides for a fund of $14,000,000 to benefit class members.
2024-04-16 12:30:00 - Press Release
Levi & Korsinsky, Llp Notifies Shareholders Of Corcept Therapeutics Incorporated (cort) An Upcoming Claims Deadline In A Class Action Settlement
New york, ny / accesswire / april 16, 2024 / levi & korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against corcept therapeutics incorporated (nasdaq: cort). the settlement provides for a fund of $14,000,000 to benefit class members.
2024-04-01 08:00:00 - Press Release
Corcept Completes Enrollment In Phase 3 Gradient Trial Of Relacorilant In Patients With Adrenal Cushing's Syndrome
Menlo park, calif., april 01, 2024 (globe newswire) -- corcept therapeutics incorporated (nasdaq: cort), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in gradient, a phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with cushing's syndrome (hypercortisolism) caused by an adrenal adenoma or adrenal hyperplasia.
2024-02-15 16:07:00 - Press Release
Corcept Therapeutics Announces Fourth Quarter And Full-year 2023 Audited Financial Results And Provides Corporate Update
Menlo park, calif., feb. 15, 2024 (globe newswire) -- corcept therapeutics incorporated (nasdaq: cort), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended december 31, 2023.
2024-02-15 16:02:00 - Press Release
Corcept Announces Preliminary Results From Prevalence Phase Of Catalyst Clinical Trial
Menlo park, calif., feb. 15, 2024 (globe newswire) -- corcept therapeutics incorporated (nasdaq: cort), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced preliminary results from the prevalence phase of its ongoing catalyst study of cushing's syndrome (hypercortisolism) in patients with difficult-to-control type 2 diabetes. with a planned enrollment of 1,000 patients, catalyst is the largest study ever conducted to establish the prevalence of hypercortisolism in this patient population.
Latest News
2024-04-17 13:01:17 - Zacks Investment Research
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2024-04-17 08:30:31 - Zacks Investment Research
New Strong Buy Stocks for April 17th
BYRN, YMAB, SAND, CORT and ENVB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
2024-04-16 12:35:20 - Zacks Investment Research
Corcept (CORT) Completes Enrollment in Phase II ALS Study
The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.
2024-04-09 12:11:05 - Zacks Investment Research
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.
2024-03-25 11:20:19 - Zacks Investment Research
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
2024-02-16 14:36:05 - Zacks Investment Research
Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow
Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
2024-02-15 21:50:02 - Seeking Alpha
Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript
2024-02-08 16:05:00 - GlobeNewsWire
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2023 financial results and provide a corporate update on February 15, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
2024-01-29 13:11:34 - Zacks Investment Research
Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2024-01-09 12:02:15 - Zacks Investment Research
Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024
Corcept (CORT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise on robust 2024 revenue guidance.